Boryung Corporation (003850.KS) Stock
Boryung Corporation

Company profile
Boryung reported revenue of 1.02 trillion KRW for fiscal year 2025, about flat from fiscal year 2024, and net income of 64.30 billion KRW. That is a net profit margin of 6.3% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 255.35 billion KRW, up 6.2% from a year before. In Q1 2026 it reported net income of 41.44 billion KRW, against net income of 349.33 million KRW a year earlier. Our analysis of its filings shows revenue growing from 859.63 billion KRW in fiscal year 2023 to 1.02 trillion KRW in fiscal year 2025, 8.8% a year on average.
What stands out
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Boryung Corporation
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Largest shareholders
- Boryung Holdings Co., Ltd.50.80%
- Eun-Sun Kim8.326 %8.33%
- Boryung Corporation4.19%
- National Pension Service of Korea4.12%
- Medience Co., Ltd.3.55%
Share of the company, as of September 25, 2026
Leadership
- Jung-Gyun Kim — Chairman & CEO, 40
- Daniel Chang — Chief Executive Officer of Pharma Biz
- Sung Jin Kim — Chief Strategy Officer & Director, 38
How much revenue does Boryung make?
Boryung reported 1.02 trillion KRW in revenue for fiscal year 2025, about flat from 1.02 trillion KRW in fiscal year 2024. In Q1 2026 revenue was 255.35 billion KRW.
What companies are similar to Boryung?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Daewoong Pharmaceutical Co., Ltd (069620.KS), HK inno.N Corporation (195940.KQ), Chong Kun Dang Pharmaceutical Corp. (185750.KS), Daewoong Co., Ltd. (003090.KS).
How has Boryung's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 627.28 billion KRW; FY2022, 760.48 billion KRW; FY2023, 859.63 billion KRW; FY2024, 1.02 trillion KRW; FY2025, 1.02 trillion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Boryung Corporation (003850.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/003850.KS